U.S. Physical Therapy Reports Third Quarter 2024 Results
U.S. Physical Therapy reported record quarterly patient volume for Q3 2024. Key highlights include: Adjusted EBITDA of $21.1 million, up from $18.6 million in Q3 2023; total revenue from physical therapy operations increased 9.3% to $142.7 million; net rate per patient visit increased 3.2% to $105.65. The company closed 32 clinics and added 12 new ones, bringing total clinic count to 700. Industrial injury prevention services revenue grew 29.9% to $25.3 million. Notable acquisitions include a 70% stake in an eight-clinic practice and a 50% interest in a management services organization overseeing 50 clinics.
U.S. Physical Therapy ha riportato un volume record di pazienti trimestrale per il Q3 2024. I punti salienti includono: un EBITDA rettificato di 21,1 milioni di dollari, in aumento rispetto ai 18,6 milioni di dollari del Q3 2023; il fatturato totale delle operazioni di fisioterapia è aumentato del 9,3% a 142,7 milioni di dollari; il costo medio per visita del paziente è aumentato del 3,2% a 105,65 dollari. L'azienda ha chiuso 32 cliniche e ne ha aperte 12 nuove, portando il numero totale delle cliniche a 700. I ricavi dei servizi di prevenzione degli infortuni industriali sono cresciuti del 29,9% a 25,3 milioni di dollari. Tra le acquisizioni significative c'è una partecipazione del 70% in uno studio con otto cliniche e un interesse del 50% in un'organizzazione di servizi di gestione che supervisiona 50 cliniche.
U.S. Physical Therapy reportó un volumen trimestral de pacientes récord para el Q3 2024. Los aspectos más destacados incluyen: un EBITDA ajustado de 21.1 millones de dólares, un incremento desde 18.6 millones en Q3 2023; los ingresos totales de las operaciones de fisioterapia aumentaron un 9.3% a 142.7 millones de dólares; la tarifa neta por visita de paciente aumentó un 3.2% a 105.65 dólares. La compañía cerró 32 clínicas y añadió 12 nuevas, llevando el total de clínicas a 700. Los ingresos por servicios de prevención de lesiones industriales crecieron un 29.9% a 25.3 millones de dólares. Las adquisiciones notables incluyen una participación del 70% en una práctica de ocho clínicas y un interés del 50% en una organización de servicios de gestión que supervisa 50 clínicas.
미국 물리치료는 2024년 3분기 분기 환자 수 기록을 보고했습니다. 주요 하이라이트는 다음과 같습니다: 조정 EBITDA가 2,110만 달러로, 2023년 3분기의 1,860만 달러에서 증가했습니다; 물리치료 운영의 총 수익은 9.3% 증가하여 1억 4,270만 달러에 달했습니다; 환자 방문당 순요금은 3.2% 증가하여 105.65달러에 달했습니다. 회사는 32개의 클리닉을 폐쇄하고 12개의 새로운 클리닉을 추가하여 총 클리닉 수를 700개로 늘렸습니다. 산업 재해 예방 서비스 수익은 29.9% 증가하여 2,530만 달러가 되었습니다. 주목할 만한 인수에는 8개 클리닉의 70% 지분과 50개 클리닉을 감독하는 관리 서비스 조직의 50% 지분이 포함됩니다.
U.S. Physical Therapy a annoncé un volume de patients record pour le trimestre du T3 2024. Les points clés incluent : un EBITDA ajusté de 21,1 millions de dollars, en hausse par rapport à 18,6 millions de dollars au T3 2023 ; le chiffre d'affaires total des opérations de physiothérapie a augmenté de 9,3 % pour atteindre 142,7 millions de dollars ; le tarif net par consultation de patient a augmenté de 3,2 % pour atteindre 105,65 dollars. L'entreprise a fermé 32 cliniques et en a ouvert 12 nouvelles, portant le nombre total de cliniques à 700. Les revenus des services de prévention des blessures industrielles ont crû de 29,9 % pour atteindre 25,3 millions de dollars. Parmi les acquisitions notables figurent une participation de 70 % dans une pratique de huit cliniques et un intérêt de 50 % dans une organisation de services de gestion supervisant 50 cliniques.
U.S. Physical Therapy meldete ein rekordverdächtiges Patientenvolumen im Quartal für das Q3 2024. Zu den wichtigsten Highlights gehören: ein bereinigtes EBITDA von 21,1 Millionen Dollar, ein Anstieg von 18,6 Millionen Dollar im Q3 2023; der Gesamtumsatz aus den physikalischen Therapiediensten stieg um 9,3% auf 142,7 Millionen Dollar; der Nettostundensatz pro Patientenbesuch erhöhte sich um 3,2% auf 105,65 Dollar. Das Unternehmen schloss 32 Kliniken und fügte 12 neue hinzu, was die Gesamtzahl der Kliniken auf 700 brachte. Die Einnahmen aus Industrieverletzungspräventionsdiensten wuchsen um 29,9% auf 25,3 Millionen Dollar. Zu den bemerkenswerten Übernahmen gehört ein 70%iger Anteil an einer Praxis mit acht Kliniken sowie ein 50%iger Anteil an einer Verwaltungsdienstleistungsorganisation, die 50 Kliniken überwacht.
- Record high average daily patient visits of 30.1 per clinic
- Revenue from physical therapy operations increased 9.3% to $142.7 million
- Net rate per patient visit increased 3.2% to $105.65
- Industrial injury prevention services revenue grew 29.9% to $25.3 million
- Adjusted EBITDA increased by $2.5 million to $21.1 million
- $2.5 million charge (net of tax) from closure of 32 clinics
- Gross margin declined to 16.5% from 18.0% year-over-year
- Operating income decreased to $14.7 million from $15.9 million YoY
- Corporate office costs increased to 8.6% of revenue from 8.0%
Insights
Third quarter results show mixed performance with notable strategic shifts. Revenue increased 9.3% to
The closure of 32 underperforming clinics resulted in a
Industrial injury prevention services continue strong growth with
Record quarterly patient volume of 30.1 visits per clinic per day demonstrates strong market demand and operational efficiency. The strategic closure of underperforming clinics, while causing short-term costs, positions the company for improved profitability through better resource allocation.
The new MSO partnership represents a significant operational expansion, efficiently growing the network without full acquisition costs. Margin pressure from increased operating costs (
Reports Record Quarterly Patient Volume
FINANCIAL HIGHLIGHTS
-
Adjusted EBITDA (1), a non-Generally Accepted Accounting Principles (“GAAP”) measure, was
$21.1 million $2.5 million $18.6 million -
Operating Results (1), a non-GAAP measure, was
$10.4 million $1.1 million $9.2 million $0.69 $0.62 -
Net income attributable to USPH’s shareholders (“USPH Net Income”), a GAAP measure, was
$6.6 million $0.39 $2.5 million $0.9 million $0.16 $9.1 million $9.3 million $0.55 $0.51 -
Total revenue from physical therapy operations for the 2024 Third Quarter increased
$12.2 million 9.3% , to$142.7 million -
Net rate per patient visit for the 2024 Third Quarter increased to
$105.65 $102.37 3.2% , despite the1.8% Medicare rate reduction which went into effect at the beginning of 2024. The increase in net rate per patient visit reflects the Company’s strategic priority of increasing reimbursement rates through contract negotiations with commercial and other payors as well as growth in workers compensation as a percent of the Company’s overall mix of business. -
Average daily patient visits per clinic was 30.1 for the 2024 Third Quarter, a record-high for a third quarter, compared to 29.7 in the comparable prior year quarter. Total patient visits were 1,317,051 in the 2024 Third Quarter, a
6.0% increase from the 2023 Third Quarter. -
Industrial injury prevention services (“IIP”) revenue was
$25.3 million 29.9% as compared to the 2023 Third Quarter. IIP income was$5.6 million $1.2 million 27.1% , from$4.4 million - During the 2024 Third Quarter, the Company added 12 clinics and closed 32 clinics bringing its total owned and/or managed clinic count to 700 as of September 30, 2024. Results for the 32 closed clinics are included in the 2024 Third Quarter results as they were mostly closed at the end of the quarter. The closures optimize the Company’s portfolio to focus management’s efforts on growth initiatives and acquisition opportunities.
-
On August 31, 2024, the Company acquired a
70% equity interest in an eight-clinic practice with the practice owners retaining a30% equity interest. The business currently generates$5.5 million -
On October 31, 2024, the Company acquired a
50% equity interest in a management services organization that provides management and administrative services to 50 physical therapy clinics with the owners retaining a50% equity interest. Through its managed therapy providers, the Company currently generates approximately$64.0 million $12.0 million -
The Company’s Board of Directors declared a quarterly dividend of
$0.44
__________________________ |
|
(1) |
These are Non-GAAP Measures. See pages 12 to 14 of this release for the definition and reconciliation of Adjusted EBITDA, Operating Results and other Non-GAAP measures to the most directly comparable GAAP measure. |
MANAGEMENT’S COMMENTS
Chris Reading, Chief Executive Officer, said, “In any challenging environment, action is necessary to adjust one’s trajectory and our team has been taking action that will assist us in our path forward. First, we have made a number of adjustments to our footprint in terms of very important larger additions, and reciprocally in paring assets that aren’t providing an adequate return but require resources and attention. Next our operations team, along with our partners, have moved to make some subtle individual clinic adjustments that, while mostly minor in nature, aggregate to a significant amount across our current portfolio in excess of 700 clinics. These efforts will primarily begin to bear fruit in the final quarter of this year. Demand for our services remains at an all-time high with visits per clinic per day at record levels for any third quarter, and our IIP growth continues at a significant pace. Finally, all of the work that has been done on rate support is now starting to show up and that will help us meaningfully along with our cost alignment as we close out the year and begin to implement our plans for 2025.”
2024 THIRD QUARTER VERSUS 2023 THIRD QUARTER
Additional supplemental tables of financial and performance metrics are presented on page 15 of this release.
Physical Therapy Operations |
||||||||
For the Three Months Ended |
|
Variance |
||||||
September 30, 2024 |
|
September 30, 2023 |
|
$ |
|
% |
||
(In thousands, except percentages) |
||||||||
Revenue related to: |
||||||||
Mature Clinics (1) |
|
|
|
|
||||
Clinic additions (2) |
11,337 |
3,585 |
7,752 |
* |
(9) |
|||
Clinics sold or closed (3) |
1,636 |
3,046 |
(1,410) |
* |
(9) |
|||
Net Patient Revenue |
139,146 |
127,243 |
11,903 |
|
||||
Other (4) |
3,568 |
3,278 |
290 |
|
||||
Total |
142,714 |
130,521 |
12,193 |
|
||||
Operating costs (4)(7) |
119,207 |
107,016 |
12,191 |
|
||||
Gross profit (7) |
|
|
|
|
||||
Financial and operating metrics (not in thousands): |
||||||||
Net rate per patient visit (1) |
|
|
|
|
||||
Patient visits (1) |
1,317,051 |
1,242,954 |
74,097 |
|
||||
Average daily visits per clinic (1) |
30.1 |
29.7 |
0.4 |
|
||||
Gross margin |
|
|
||||||
Gross margin, excluding closure costs, Non-GAAP (6)(8) |
|
|
||||||
Salaries and related costs per visit, clinics (5) |
|
|
|
|
||||
Operating costs per visit, clinics (5)(7) |
|
|
|
|
||||
Operating costs per visit, clinics, excluding closure costs (5)(6) |
|
|
|
|
||||
|
||||||||
__________________________ |
||||||||
(1) See Glossary of Terms - Revenue Metrics for definitions. |
||||||||
(2) Includes 33 clinics added during the nine months ended September 30, 2024 and 46 clinic added during the year ended December 31, 2023. |
||||||||
(3) Includes 43 clinics closed during the nine months ended September 30, 2024 and 15 clinics closed during the year ended December 31, 2023. |
||||||||
(4) Includes revenues and costs from management contracts. |
||||||||
(5) Per visit costs excludes management contract costs. |
||||||||
(6) Excludes |
||||||||
(7) Includes |
||||||||
(8) Refer to reconciliation of non-GAAP measures to most comparable GAAP measures for more information. |
||||||||
(9) Not meaningful. |
||||||||
Net revenue from physical therapy operations increased
Operating costs from physical therapy operations increased
Gross profit from physical therapy operations in the 2024 Third Quarter was
__________________________ |
|
(1) |
These are Non-GAAP Measures. Refer to reconciliation of non-GAAP measures to most comparable GAAP measures for more information. |
Industrial Injury Prevention Services |
|||||||
For the Three Months Ended |
|
Variance |
|||||
September 30, 2024 |
|
September 30, 2023 |
|
$ |
|
% |
|
(In thousands, except percentages) |
|||||||
Net revenue |
|
|
|
|
|||
Operating costs |
19,695 |
15,062 |
4,633 |
|
|||
Gross profit |
|
|
|
|
|||
Gross margin |
|
|
|||||
IIP revenues increased
Corporate Office and Other Expenses
Corporate office costs were
Operating income was
Interest expense decreased
Interest income from investing excess cash (primarily proceeds from the secondary offering sale of the Company’s stock completed in May 2023) in a high-yield savings account decreased to
The Company revalued contingent and put-right liabilities related to certain acquisitions and recognized a net non-cash expense (an increase in the related liabilities) of
The provision for income taxes was
__________________________ |
|
(1) |
These are Non-GAAP Measures. Refer to reconciliation of non-GAAP measures to most comparable GAAP measures for more information. |
USPH Net Income and Non-GAAP Measures
Net income attributable to non-controlling interest (temporary and permanent) was
USPH Net Income was
Non-GAAP Adjusted EBITDA (1) was
__________________________ |
|
(1) |
These are Non-GAAP Measures. See pages 12 to 14 of this release for the definition and reconciliation of Adjusted EBITDA, Operating Results and other Non-GAAP measures to the most directly comparable GAAP measure. |
NINE MONTHS ENDED SEPTEMBER 30, 2024 VERSUS NINE MONTHS ENDED SEPTEMBER 30, 2023
Total net revenue for the nine months ended September 30, 2024 (“2024 Nine Months”) increased
Revenues from physical therapy operations increased
Revenues from IIP increased
Corporate office costs were
Operating income was
Other expenses were
The provision for income tax was
USPH Net Income was
Non-GAAP Adjusted EBITDA (1) increased
For additional information on 2024 Nine Months results, please refer to the Company’s Quarterly Report on Form 10-Q which is expected to be filed with the Securities and Exchange Commission on November 8, 2024.
__________________________ |
|
(1) |
These are Non-GAAP Measures. See pages 12 to 14 of this release for the definition and reconciliation of Adjusted EBITDA, Operating Results and other Non-GAAP measures to the most directly comparable GAAP measure. |
BALANCE SHEET AND CASH FLOW
Total cash and cash equivalents were
RECENT ACQUISITIONS
On August 31, 2024, the Company acquired a
On October 31, 2024, the Company acquired a
The Company’s strategy is to continue acquiring multi-clinic outpatient physical therapy practices, to develop outpatient physical therapy clinics as satellites in existing partnerships and to continue acquiring companies that provide industrial injury prevention services.
QUARTERLY DIVIDEND
The Company’s Board of Directors declared a quarterly dividend of
CONFERENCE CALL INFORMATION
FORWARD LOOKING STATEMENTS
This press release contains statements that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as amended. These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes,” “expects,” “intends,” “plans,” “appear,” “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we expect. Included among such statements may be those relating to new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
- revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- the impact of future public health crises and epidemics/pandemics, such as was the case with the novel strain of COVID-19 and its variants;
- one of our acquisition agreements contains a put right related to a future purchase of a majority interest in a separate company;
- the impact of future vaccinations and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations;
- our debt and financial obligations could adversely affect our financial condition, our ability to obtain future financing and our ability to operate our business;
- changes as the result of government enacted national healthcare reform;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs;
- revenue and earnings expectations;
- contingent consideration provisions in certain our acquisition agreements, the value of which may impact future financial results;
- legal actions, which could subject us to increased operating costs and uninsured liabilities;
- general economic conditions, including but not limited to inflationary and recessionary periods;
-
actual or perceived events involving banking volatility or limited liability, defaults or other adverse developments that affect the
U.S. or international financial systems, may result in market wide liquidity problems which could have a material and adverse impact on our available cash and results of operations; - our business depends on hiring, training, and retaining qualified employees;
- availability and cost of qualified physical therapists;
- competitive environment in the industrial injury prevention services business, which could result in the termination or non-renewal of contractual service arrangements and other adverse financial consequences for that service line;
- our ability to identify and complete acquisitions, and the successful integration of the operations of the acquired businesses;
- impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests);
- maintaining our information technology systems with adequate safeguards to protect against cyber-attacks and preserve data privacy;
- a security breach of our or our third-party vendors’ information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act, or may interfere with our ability to file and process claims for payment which could interfere with our collection of revenues from third party payors;
- maintaining clients for which we perform management, IIP services, and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;
- enforcing our noncompetition covenants with employed therapists;
- maintaining adequate internal controls;
- maintaining necessary insurance coverage;
- availability, terms, and use of capital; and
- weather and other seasonal factors.
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. For additional information regarding these and other risks and uncertainties, that could cause actual results to differ materially from those contained in our forward-looking statements, please refer to “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on February 29, 2024 and any risk factors contained in subsequent quarterly and annual reports we file with the SEC. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement as a result of new information, future events, or otherwise, except as required by law.
GLOSSARY OF TERMS – REVENUE METRICS
Mature clinics are clinics opened or acquired prior to January 1, 2023, and are still operating as of the balance sheet date.
Net rate per patient visit is net patient revenue related to our physical therapy operations divided by total number of patient visits (defined below) during the periods presented.
Patient visits is the number of unique patient visits during the periods presented.
Average daily visits per clinic is patient visits divided by the number of days in which normal business operations were conducted during the periods presented and further divided by the average number of clinics in operation during the periods presented.
ABOUT U.S. PHYSICAL THERAPY, INC.
Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 750 outpatient physical therapy clinics in 43 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
|
|||||||||||
For the Three Months Ended |
|
For the Nine Months Ended |
|||||||||
September 30, 2024 |
|
September 30, 2023 |
|
September 30, 2024 |
|
September 30, 2023 |
|||||
|
|
|
|
|
|
||||||
Net patient revenue |
$ |
139,146 |
$ |
127,243 |
$ |
410,492 |
$ |
383,104 |
|||
Other revenue |
|
28,887 |
|
22,764 |
|
80,406 |
|
66,897 |
|||
Net revenue |
|
168,033 |
|
150,007 |
|
490,898 |
|
450,001 |
|||
Operating cost: |
|||||||||||
Salaries and related costs |
|
99,835 |
|
89,846 |
|
289,900 |
|
262,757 |
|||
Rent, supplies, contract labor and other |
|
33,914 |
|
30,678 |
|
100,430 |
|
91,490 |
|||
Provision for credit losses |
|
1,721 |
|
1,525 |
|
5,065 |
|
4,600 |
|||
Clinic closure costs - lease and other |
|
3,432 |
|
29 |
|
4,109 |
|
161 |
|||
Total operating cost |
|
138,902 |
|
122,078 |
|
399,504 |
|
359,008 |
|||
Gross profit |
|
29,131 |
|
27,929 |
|
91,394 |
|
90,993 |
|||
Corporate office costs |
|
14,385 |
|
12,048 |
|
42,719 |
|
38,052 |
|||
Operating income |
|
14,746 |
|
15,881 |
|
48,675 |
|
52,941 |
|||
Other income (expense): |
|||||||||||
Interest expense, debt and other |
|
(2,018) |
|
(2,101) |
|
(5,966) |
|
(7,293) |
|||
Interest income from investments |
|
1,018 |
|
1,673 |
|
3,635 |
|
2,191 |
|||
Change in fair value of contingent earn-out consideration |
|
(1,899) |
|
187 |
|
(5,332) |
|
197 |
|||
Change in revaluation of put-right liability |
|
168 |
|
(145) |
|
(136) |
|
(344) |
|||
Equity in earnings of unconsolidated affiliate |
|
231 |
|
206 |
|
750 |
|
806 |
|||
Relief Funds |
|
- |
|
- |
|
- |
|
467 |
|||
Other |
|
90 |
|
78 |
|
261 |
|
305 |
|||
Total other income (expense) |
|
(2,410) |
|
(102) |
|
(6,788) |
|
(3,671) |
|||
Income before taxes |
|
12,336 |
|
15,779 |
|
41,887 |
|
49,270 |
|||
Provision for income taxes |
|
2,559 |
|
3,557 |
|
8,781 |
|
10,757 |
|||
Net income |
|
9,777 |
|
12,222 |
|
33,106 |
|
38,513 |
|||
Less: Net income attributable to non-controlling interest: |
|||||||||||
Redeemable non-controlling interest - temporary equity |
|
(1,998) |
|
(1,976) |
|
(7,539) |
|
(7,616) |
|||
Non-controlling interest - permanent equity |
|
(1,151) |
|
(992) |
|
(3,387) |
|
(3,314) |
|||
|
(3,149) |
|
(2,968) |
|
(10,926) |
|
(10,930) |
||||
Net income attributable to USPH shareholders |
$ |
6,628 |
$ |
9,254 |
$ |
22,180 |
$ |
27,583 |
|||
Basic and diluted earnings per share attributable to USPH shareholders (1) |
$ |
0.39 |
$ |
0.51 |
$ |
1.32 |
$ |
1.72 |
|||
Shares used in computation - basic and diluted |
|
15,077 |
|
14,987 |
|
15,055 |
|
13,918 |
|||
Dividends declared per common share |
$ |
0.44 |
$ |
0.43 |
$ |
1.32 |
$ |
1.29 |
|||
(1) See page 13 of this press release for the calculation of basic and diluted earnings per share. |
|||||||||||
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
|
|||||||||||
|
For the Three Months Ended |
|
For the Nine Months Ended |
||||||||
|
September 30, 2024 |
|
September 30, 2023 |
|
September 30, 2024 |
|
September 30, 2023 |
||||
|
|||||||||||
Net income |
$ |
9,777 |
$ |
12,222 |
$ |
33,106 |
$ |
38,513 |
|||
Other comprehensive (loss) gain: |
|||||||||||
Unrealized (loss) gain on cash flow hedge |
|
(3,687) |
|
1,276 |
|
(1,937) |
|
2,340 |
|||
Tax effect at statutory rate (federal and state) |
|
942 |
|
(326) |
|
495 |
|
(598) |
|||
Comprehensive income |
$ |
7,032 |
$ |
13,172 |
$ |
31,664 |
$ |
40,255 |
|||
|
|||||||||||
Comprehensive income attributable to non-controlling interest |
|
(3,149) |
|
(2,968) |
|
(10,926) |
|
(10,930) |
|||
Comprehensive income attributable to USPH shareholders |
$ |
3,883 |
$ |
10,204 |
$ |
20,738 |
$ |
29,325 |
|||
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
|
|||||
September 30, 2024 |
|
December 31, 2023 |
|||
ASSETS |
(unaudited) |
|
|
||
Current assets: |
|
|
|
||
Cash and cash equivalents |
$ |
116,959 |
$ |
152,825 |
|
Patient accounts receivable, less provision for credit losses of |
|
57,022 |
|
51,866 |
|
Accounts receivable - other |
|
20,056 |
|
17,854 |
|
Other current assets |
|
10,833 |
|
10,830 |
|
Total current assets |
|
204,870 |
|
233,375 |
|
Fixed assets: |
|||||
Furniture and equipment |
|
66,782 |
|
63,982 |
|
Leasehold improvements |
|
48,385 |
|
46,941 |
|
Fixed assets, gross |
|
115,167 |
|
110,923 |
|
Less accumulated depreciation and amortization |
|
(88,602) |
|
(84,821) |
|
Fixed assets, net |
|
26,565 |
|
26,102 |
|
Operating lease right-of-use assets |
|
103,938 |
|
103,431 |
|
Investment in unconsolidated affiliate |
|
12,168 |
|
12,256 |
|
Goodwill |
|
554,642 |
|
509,571 |
|
Other identifiable intangible assets, net |
|
124,309 |
|
109,682 |
|
Other assets |
|
2,699 |
|
2,821 |
|
Total assets |
$ |
1,029,191 |
$ |
997,238 |
|
|
|||||
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST, USPH SHAREHOLDERS’ EQUITY AND NON-CONTROLLING INTEREST |
|||||
Current liabilities: |
|||||
Accounts payable - trade |
$ |
6,361 |
$ |
3,898 |
|
Accrued expenses |
|
64,506 |
|
55,344 |
|
Current portion of operating lease liabilities |
|
34,828 |
|
35,252 |
|
Current portion of term loan and notes payable |
|
9,605 |
|
7,691 |
|
Total current liabilities |
|
115,300 |
|
102,185 |
|
Notes payable, net of current portion |
|
534 |
|
1,289 |
|
Term loan, net of current portion and deferred financing costs |
|
132,382 |
|
137,702 |
|
Deferred taxes |
|
24,913 |
|
24,815 |
|
Operating lease liabilities, net of current portion |
|
77,001 |
|
76,653 |
|
Other long-term liabilities |
|
8,343 |
|
2,356 |
|
Total liabilities |
|
358,473 |
|
345,000 |
|
|
|||||
Redeemable non-controlling interest - temporary equity |
|
186,602 |
|
174,828 |
|
|
|||||
Commitments and Contingencies |
|||||
|
|||||
U.S. Physical Therapy, Inc. ("USPH") shareholders’ equity: |
|||||
Preferred stock, |
|
- |
|
- |
|
Common stock, |
|
172 |
|
172 |
|
Additional paid-in capital |
|
287,002 |
|
281,096 |
|
Accumulated other comprehensive gain |
|
1,339 |
|
2,782 |
|
Retained earnings |
|
225,873 |
|
223,772 |
|
Treasury stock at cost, 2,214,737 shares |
|
(31,628) |
|
(31,628) |
|
Total USPH shareholders’ equity |
|
482,758 |
|
476,194 |
|
Non-controlling interest - permanent equity |
|
1,358 |
|
1,216 |
|
Total USPH shareholders' equity and non-controlling interest - permanent equity |
|
484,116 |
|
477,410 |
|
Total liabilities, redeemable non-controlling interest, USPH shareholders' equity and non-controlling interest - permanent equity |
$ |
1,029,191 |
$ |
997,238 |
|
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
|
|||||
|
For the Nine Months Ended |
||||
|
September 30, 2024 |
|
September 30, 2023 |
||
OPERATING ACTIVITIES |
|
|
|
||
Net income including non-controlling interest |
$ |
33,106 |
|
$ |
38,513 |
Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities: |
|
||||
Depreciation and amortization |
|
12,996 |
|
|
11,582 |
Provision for credit losses |
|
5,065 |
|
|
4,600 |
Equity-based awards compensation expense |
|
5,837 |
|
|
5,451 |
Amortization of debt issue costs |
|
317 |
|
|
315 |
Change in deferred income taxes |
|
605 |
|
|
5,393 |
Change in revaluation of put-right liability |
|
136 |
|
|
344 |
Change in fair value of contingent earn-out consideration |
|
5,332 |
|
|
(197) |
Equity of earnings in unconsolidated affiliate |
|
(750) |
|
|
(806) |
Other |
|
||||
Loss (gain) on sale of fixed assets |
|
280 |
|
|
(106) |
Others |
|
(169) |
|
|
- |
Changes in operating assets and liabilities: |
|
||||
Increase in patient accounts receivable |
|
(8,870) |
|
|
(5,415) |
Increase in accounts receivable - other |
|
(960) |
|
|
(1,631) |
(Increase) decrease in other current and long term assets |
|
(1,808) |
|
|
2,489 |
Increase (decrease) in accounts payable and accrued expenses |
|
5,003 |
|
|
(5,609) |
(Decrease) increase in other long-term liabilities |
|
(589) |
|
|
220 |
Net cash provided by operating activities |
|
55,531 |
|
|
55,143 |
|
|
||||
INVESTING ACTIVITIES |
|
||||
Purchase of fixed assets |
|
(6,697) |
|
|
(7,074) |
Purchase of majority interest in businesses, net of cash acquired |
|
(41,196) |
|
|
(22,994) |
Purchase of redeemable non-controlling interest, temporary equity |
|
(6,957) |
|
|
(7,804) |
Purchase of non controlling interest, permanent equity |
|
(756) |
|
|
(262) |
Proceeds on sale of redeemable non-controlling interest, temporary equity |
|
229 |
|
|
815 |
Proceeds on sale of non-controlling interest, permanent equity |
|
26 |
|
|
30 |
Distributions from unconsolidated affiliate |
|
838 |
|
|
681 |
Other |
|
(84) |
|
|
7 |
Net cash used in investing activities |
|
(54,597) |
|
|
(36,601) |
|
|
||||
FINANCING ACTIVITIES |
|
||||
Cash dividends paid to shareholders |
|
(19,898) |
|
|
(17,683) |
Distributions to non-controlling interest, permanent and temporary equity |
|
(11,399) |
|
|
(11,777) |
Principal payments on notes payable |
|
(1,726) |
|
|
(2,874) |
Payments on term loan |
|
(3,750) |
|
|
(2,813) |
Payments on revolving facility |
|
- |
|
|
(55,000) |
Proceeds from issuance of common stock pursuant to the secondary public offering, net of issuance costs |
|
- |
|
|
163,646 |
Proceeds from revolving facility |
|
- |
|
|
24,000 |
Other |
|
(27) |
|
|
50 |
Net cash (used in) provided by financing activities |
|
(36,800) |
|
|
97,549 |
|
|
||||
Net (decrease) increase in cash and cash equivalents |
|
(35,866) |
|
|
116,091 |
Cash and cash equivalents - beginning of period |
|
152,825 |
|
|
31,594 |
Cash and cash equivalents - end of period |
$ |
116,959 |
|
$ |
147,685 |
|
|
||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION |
|
||||
Cash paid during the period for: |
|
||||
Income taxes |
$ |
5,759 |
|
$ |
2,731 |
Interest paid |
|
5,630 |
|
|
6,992 |
Non-cash investing and financing transactions during the period: |
|
||||
Purchase of interest in businesses - seller financing portion |
|
7,395 |
|
|
1,860 |
Initial contingent consideration related to purchase of interest of businesses |
|
5,940 |
|
|
200 |
Offset of notes receivable associated with purchase of redeemable non-controlling interest |
|
627 |
|
|
- |
Notes payable related to purchase of redeemable non-controlling interest, temporary equity |
|
66 |
|
|
1,017 |
Notes payable related to purchase of non-controlling interest, permanent equity |
|
- |
|
|
200 |
Notes receivable related to sale of redeemable non-controlling interest, temporary equity |
|
2,075 |
|
|
3,064 |
Notes receivable related to the sale of non-controlling interest, permanent equity |
$ |
282 |
|
$ |
397 |
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
ADJUSTED EBITDA AND OPERATING RESULTS
The following tables provide details of the basic and diluted earnings per share computation and reconcile net income attributable to USPH shareholders calculated in accordance with GAAP to Adjusted EBITDA, Operating Results and other non-GAAP measures. Management believes providing Adjusted EBITDA, Operating Results, and other non-GAAP measures to investors is useful information for comparing the Company's period-to-period results as well as for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures. Management uses Adjusted EBITDA, Operating Results and other non-GAAP measures, which eliminate certain items described above that can be subject to volatility and unusual costs, as the principal measures to evaluate and monitor financial performance period over period.
Adjusted EBITDA, a non-GAAP measure, is defined as net income attributable to USPH shareholders before interest income, interest expense, taxes, depreciation, amortization, change in fair value of contingent earn-out consideration, payments received from the federal government under the Corona virus Aid, Relief and Economic Security Act (“Relief Funds”), changes in revaluation of put-right liability, equity-based awards compensation expense, clinic closure costs, business acquisition related costs and other income and related portions for non-controlling interests.
Operating Results, a non-GAAP measure, equals net income attributable to USPH shareholders less, changes in revaluation of a put-right liability, Relief Funds, clinic closure costs, changes in fair value of contingent earn-out consideration, business acquisition related costs and any allocations to non-controlling interests, all net of taxes. Operating Results per share also excludes the impact of the revaluation of redeemable non-controlling interest and the associated tax impact.
Adjusted EBITDA, Operating Results and other non-GAAP measures are not measures of financial performance under GAAP. Adjusted EBITDA, Operating Results and other non-GAAP measures should not be considered in isolation or as an alternative to, or substitute for, net income attributable to USPH shareholders presented in the consolidated financial statements.
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
|
|||||||||||
|
For the Three Months Ended |
|
For the Nine Months Ended |
||||||||
|
September 30, 2024 |
|
September 30, 2023 |
|
September 30, 2024 |
|
September 30, 2023 |
||||
(In thousands, except per share data) |
|||||||||||
Adjusted EBITDA (a non-GAAP measure) |
|
|
|
|
|
|
|
||||
Net income attributable to USPH shareholders |
$ |
6,628 |
$ |
9,254 |
$ |
22,180 |
$ |
27,583 |
|||
Adjustments: |
|||||||||||
Provision for income taxes |
|
2,559 |
|
3,557 |
|
8,781 |
|
10,757 |
|||
Depreciation and amortization |
|
4,387 |
|
3,966 |
|
12,996 |
|
11,582 |
|||
Interest expense, debt and other, net |
|
2,018 |
|
2,101 |
|
5,966 |
|
7,293 |
|||
Equity-based awards compensation expense |
|
1,921 |
|
1,859 |
|
5,837 |
|
5,451 |
|||
Interest income from investments |
|
(1,018) |
|
(1,673) |
|
(3,635) |
|
(2,191) |
|||
Change in revaluation of put-right liability |
|
(168) |
|
(187) |
|
136 |
|
(197) |
|||
Change in fair value of contingent earn-out consideration |
|
1,899 |
|
145 |
|
5,332 |
|
344 |
|||
Relief Funds |
|
- |
|
- |
|
- |
|
(467) |
|||
Clinic closure costs (1) |
|
3,432 |
|
29 |
|
4,109 |
|
161 |
|||
Business acquisition related costs (2) |
|
314 |
|
- |
|
314 |
|
- |
|||
Other income |
|
(90) |
|
(78) |
|
(261) |
|
(305) |
|||
Allocation to non-controlling interests |
|
(811) |
|
(361) |
|
(1,789) |
|
(1,138) |
|||
$ |
21,071 |
$ |
18,612 |
$ |
59,966 |
$ |
58,873 |
||||
Operating Results (a non-GAAP measure) |
|||||||||||
Net income attributable to USPH shareholders |
$ |
6,628 |
$ |
9,254 |
$ |
22,180 |
$ |
27,583 |
|||
Adjustments: |
|||||||||||
Change in fair value of contingent earn-out consideration |
|
1,899 |
|
145 |
|
5,332 |
|
344 |
|||
Change in revaluation of put-right liability |
|
(168) |
|
(187) |
|
136 |
|
(197) |
|||
Clinic closure costs (1) |
|
3,432 |
|
29 |
|
4,109 |
|
161 |
|||
Business acquisition related costs (2) |
|
314 |
|
- |
|
314 |
|
- |
|||
Relief Funds |
|
- |
|
- |
|
(467) |
|||||
Allocation to non-controlling interests |
|
(429) |
|
(3) |
|
(513) |
|
(19) |
|||
Tax effect at statutory rate (federal and state) |
|
(1,290) |
|
4 |
|
(2,396) |
|
46 |
|||
$ |
10,386 |
$ |
9,242 |
$ |
29,162 |
$ |
27,451 |
||||
Operating Results per share (a non-GAAP measure) |
$ |
0.69 |
$ |
0.62 |
$ |
1.94 |
$ |
1.97 |
|||
|
|||||||||||
Earnings per share |
|||||||||||
Computation of earnings per share - USPH shareholders: |
|||||||||||
Net income attributable to USPH shareholders |
$ |
6,628 |
$ |
9,254 |
$ |
22,180 |
$ |
27,583 |
|||
Charges to retained earnings: |
|||||||||||
Revaluation of redeemable non-controlling interest |
|
(1,097) |
|
(2,242) |
|
(3,158) |
|
(4,988) |
|||
Tax effect at statutory rate (federal and state) |
|
280 |
|
573 |
|
807 |
|
1,274 |
|||
$ |
5,811 |
$ |
7,585 |
$ |
19,829 |
$ |
23,869 |
||||
Earnings per share (basic and diluted) |
$ |
0.39 |
$ |
0.51 |
$ |
1.32 |
$ |
1.72 |
|||
Shares used in computation - basic and diluted |
|
15,077 |
|
14,987 |
|
15,055 |
|
13,918 |
|||
(1) |
Costs associated with the closure of 32 clinics during the 2024 Third Quarter and 43 clinics during the 2024 Nine Months. Closure costs in the 2023 Third Quarter and 2023 Nine Months were not material. |
(2) |
Primarily consists of legal and consulting expenses related to the acquisition of |
U. S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
|
|||||||||||||||||
Three Months Ended September 30, 2024 |
|
Three Months Ended September 30, 2023 |
|||||||||||||||
As Reported (GAAP) |
|
Closure Costs (1) |
|
As Adjusted (Non-GAAP) |
|
As Reported (GAAP) |
|
Closure Costs (1) |
|
As Adjusted (Non-GAAP) |
|||||||
|
(in thousands, except per share data and percentages) |
||||||||||||||||
Operating costs |
$ |
138,902 |
$ |
(3,432) |
$ |
135,470 |
$ |
122,078 |
$ |
(29) |
$ |
122,049 |
|||||
Gross profit |
|
29,131 |
|
3,432 |
|
32,563 |
|
27,929 |
|
29 |
|
27,958 |
|||||
Gross margin |
|
|
* |
|
|
|
|
* |
|
|
|||||||
Operating income |
|
14,746 |
|
3,432 |
|
18,178 |
|
15,881 |
|
29 |
|
15,910 |
|||||
Provision for taxes |
|
2,559 |
|
(958) |
|
1,601 |
|
3,557 |
|
(8) |
|
3,549 |
|||||
USPH Net Income |
|
6,628 |
|
2,474 |
|
9,102 |
|
9,254 |
|
21 |
|
9,275 |
|||||
Earnings per share |
$ |
0.39 |
$ |
0.16 |
$ |
0.55 |
$ |
0.51 |
$ |
- |
$ |
0.51 |
|||||
Segment information - Physical Therapy Operations |
|||||||||||||||||
Operating costs |
$ |
119,207 |
$ |
(3,432) |
$ |
115,775 |
$ |
107,016 |
$ |
(29) |
$ |
106,987 |
|||||
Gross profit |
$ |
23,507 |
$ |
3,432 |
$ |
26,939 |
$ |
23,505 |
$ |
29 |
$ |
23,534 |
|||||
Gross margin |
|
|
* |
|
|
|
|
* |
|
|
|||||||
Nine Months Ended September 30, 2024 |
Nine Months Ended September 30, 2023 |
||||||||||||||||
As Reported (GAAP) |
Closure Costs (1) |
As Adjusted (Non-GAAP) |
As Reported (GAAP) |
Closure Costs (1) |
As Adjusted (Non-GAAP) |
||||||||||||
|
(in thousands, except per share data and percentages) |
||||||||||||||||
Operating costs |
$ |
399,504 |
$ |
(4,109) |
$ |
395,395 |
$ |
359,008 |
$ |
(161) |
$ |
358,847 |
|||||
Gross profit |
|
91,394 |
|
4,109 |
|
95,503 |
|
90,993 |
|
161 |
|
91,154 |
|||||
Gross margin |
|
|
* |
|
|
|
|
* |
|
|
|||||||
Operating income |
|
48,675 |
|
4,109 |
|
52,784 |
|
52,941 |
|
161 |
|
53,102 |
|||||
Provision for taxes |
|
8,781 |
|
(1,167) |
|
7,614 |
|
10,757 |
|
(45) |
|
10,712 |
|||||
USPH Net Income |
|
22,180 |
|
2,942 |
|
25,122 |
|
27,583 |
|
116 |
|
27,699 |
|||||
Earnings per share |
$ |
1.32 |
$ |
0.20 |
$ |
1.52 |
$ |
1.72 |
$ |
0.01 |
$ |
1.73 |
|||||
Segment information - Physical Therapy Operations |
|||||||||||||||||
Operating costs |
$ |
344,270 |
$ |
(4,109) |
$ |
340,161 |
$ |
313,104 |
$ |
(161) |
$ |
312,943 |
|||||
Gross profit |
$ |
76,355 |
$ |
4,109 |
$ |
80,464 |
$ |
78,815 |
$ |
161 |
$ |
78,976 |
|||||
Gross margin |
|
|
* |
|
|
|
|
* |
|
|
|||||||
__________________________ |
|
(1) |
Costs associated with the closure of 32 and 43 clinics during the 2024 Third Quarter and 2024 Nine Months, respectively. Closure costs for the comparable prior year periods were not material. We believe that presenting this information will allow investors to evaluate the performance of the Company's business more objectively. |
| * Not meaningful | |
U.S. PHYSICAL THERAPY, INC. AND SUBSIDIARIES
|
|||||||||||||||
Revenue Metrics |
|||||||||||||||
Number of Clinics (2) |
|
Net Rate Per Patient Visit (1) |
|
Patient Visits (1) |
|
Average Daily Visits Per Clinic (1) |
|||||||||
2024 |
|
2023 |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
2024 |
|
2023 |
|
First Quarter |
679 |
647 |
|
|
1,268,002 |
1,227,490 |
29.5 |
29.8 |
|||||||
Second quarter |
681 |
656 |
|
|
1,335,335 |
1,267,140 |
30.6 |
30.4 |
|||||||
Third quarter |
661 |
672 |
|
|
1,317,051 |
1,242,954 |
30.1 |
29.7 |
|||||||
Fourth quarter |
671 |
|
1,267,842 |
|
29.9 |
||||||||||
Year |
|
|
671 |
|
|
|
|
|
|
|
5,005,426 |
|
|
|
30.0 |
__________________________ |
|
(1) |
See definition of the metrics above in the Glossary of Terms – Revenue Metrics on page 7. |
(2) |
The Company also manages clinics owned by third parties through management contracts. In addition to the clinic count shown above, as of September 30, 2024, the Company managed 39 clinics bringing the total owned/managed clinics to 700. |
Clinic Count Roll Forward (1) |
|||||||
For the Three Months Ended |
|
For the Nine Months Ended |
|||||
September 30, 2024 |
|
September 30, 2023 |
|
September 30, 2024 |
|
September 30, 2023 |
|
Number of clinics, beginning of period |
681 |
656 |
671 |
640 |
|||
Additions (2) |
12 |
19 |
33 |
40 |
|||
Closed or sold |
(32) |
(3) |
(43) |
(8) |
|||
Number of clinics, end of period |
661 |
672 |
661 |
672 |
|||
__________________________ |
|
(1) |
The Company also manages clinics owned by third parties through management contracts. In addition to the clinic count shown above, as of September 30, 2024, the Company managed 39 clinics bringing the total owned/managed clinics to 700. |
(2) |
Includes clinics added through acquisitions. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105887439/en/
U.S. Physical Therapy, Inc.
Carey Hendrickson, Chief Financial Officer
email: chendrickson@usph.com
Chris Reading, Chief Executive Officer
(713) 297-7000
Three Part Advisors
Joe Noyons
(817) 778-8424
Source: U.S. Physical Therapy, Inc.
FAQ
What was USPH's revenue growth in Q3 2024?
How many clinics did USPH close in Q3 2024?
What was USPH's earnings per share in Q3 2024?
What was USPH's average daily patient visits per clinic in Q3 2024?
